Gabapentin-600mg-100s (Gabapentin 600mg 100s)
Gabapentin Tablet
Product Images NDC 67877-429
8 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 67877-429). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Gabapentin-800mg-100s (Gabapentin 800mg 100s)
Gabapentin Equation (Gabapentin Equation)
A formula is shown for calculating creatinine clearance (CLCr), incorporating age, weight, serum creatinine levels, and an adjustment factor for female patients. It is a text panel displaying this calculation formula.*
Gabapentin-fig1 (Gabapentin Fig1)
A line graph showing the mean pain score over 8 weeks comparing placebo and Gabapentin at 3600 mg/day. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a decreasing mean pain score while placebo remains relatively constant.*
Gabapentin-fig2 (Gabapentin Fig2)
A line graph showing mean pain score over seven weeks comparing placebo and two dosages of gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks with a 3-week dose titration period followed by a 4-week fixed dose period, and the y-axis represents mean pain score from 0 to 10. Gabapentin groups show a greater reduction in pain score than placebo over time.*
Gabapentin-fig3 (Gabapentin Fig3)
A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. Study 1 compares placebo (PBO) at 12% to Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14% to Gabapentin 1800 mg and 2400 mg at 32% and 34%, respectively, with significance levels indicated for GBP groups.*
Gabapentin-fig4 (Gabapentin Fig4)
A scatter plot chart comparing percentage difference against daily dose in milligrams (600, 900, 1200, 1800 mg) for Gabapentin across three studies labeled a, b, and c. The chart displays data points for each study at various doses with a legend indicating study identifiers by color and shape in black, gray, and white squares.*
Gabapentin-structure (Gabapentin Structure)
Chemical structure of the active ingredient Gabapentin, displaying its molecular framework including a cyclohexane ring attached to amino and carboxyl functional groups.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
